<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949455</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000640393</org_study_id>
    <secondary_id>OCTG-LaMB</secondary_id>
    <secondary_id>BL-2007-02</secondary_id>
    <secondary_id>EUDRACT-2007-001826-28</secondary_id>
    <secondary_id>EU-20929</secondary_id>
    <nct_id>NCT00949455</nct_id>
  </id_info>
  <brief_title>A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium</brief_title>
  <acronym>LaMB</acronym>
  <official_title>A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth. It is not yet known whether lapatinib ditosylate is more&#xD;
      effective than a placebo in killing tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II/III trial is studying how well lapatinib ditosylate works&#xD;
      compared to a placebo in treating patients with stage IV bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare progression-free survival in patients with HER1- and/or HER2-overexpressing&#xD;
           stage IV bladder cancer who have been randomized to maintenance therapy with lapatinib&#xD;
           ditosylate or placebo following first-line chemotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare overall survival between these patient groups.&#xD;
&#xD;
        -  Evaluate the safety and tolerability of the regimens in these patients.&#xD;
&#xD;
        -  Assess and compare quality of life between these patient groups.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to ECOG performance&#xD;
      status and response to first line chemotherapy (complete or partial response vs stable&#xD;
      disease). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral lapatinib ditosylate once daily in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo once daily in the absence of disease progression&#xD;
           or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo quality of life assessment by EORTC QLQ-C30 at baseline and every 4 weeks&#xD;
      during study treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Disease Progression - at least 20% increase in the sum of longest diameters of target lesions.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Tykerb</other_name>
    <other_name>Tyverb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed transitional cell carcinoma of the bladder&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
               -  Metastatic or locally advanced disease&#xD;
&#xD;
          -  HER1- and/or HER2-positive disease, defined by the following criteria:&#xD;
&#xD;
               -  2+ or 3+ intensity on IHC&#xD;
&#xD;
          -  Able to commence the study treatment within 10 weeks of completing chemotherapy&#xD;
&#xD;
          -  Must have achieved objective response or stable disease following 4-8 courses of&#xD;
             first-line chemotherapy&#xD;
&#xD;
               -  No progression with first-line chemotherapy for metastatic disease&#xD;
&#xD;
               -  Any widely accepted chemotherapy regimen for bladder cancer allowed&#xD;
&#xD;
               -  Patients who did not receive cisplatin are eligible&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  ANC ≥ 1.0 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 75 x 10^9/L&#xD;
&#xD;
          -  ALT/AST &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 3.0 ULN AND/OR creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  LVEF ≥ 50% (as assessed by quantitative echocardiogram or MUGA)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No current active hepatic or biliary disease, except for any of the following:&#xD;
&#xD;
               -  Gilbert's syndrome&#xD;
&#xD;
               -  Asymptomatic gallstones&#xD;
&#xD;
               -  Liver metastases&#xD;
&#xD;
               -  Stable chronic liver disease per investigator assessment&#xD;
&#xD;
          -  No known hypersensitivity to the study medication&#xD;
&#xD;
          -  No history of prior or concurrent other neoplasms, except for:&#xD;
&#xD;
               -  Any non life-threatening tumours that have been curatively treated.&#xD;
&#xD;
               -  Prostate cancer isolated to the prostate gland&#xD;
&#xD;
          -  No significant cardiac disease, including any of the following:&#xD;
&#xD;
               -  Angina pectoris&#xD;
&#xD;
               -  Severe cardiac arrhythmia requiring medication&#xD;
&#xD;
               -  Severe conduction abnormalities&#xD;
&#xD;
               -  Clinically significant valvular disease&#xD;
&#xD;
               -  Cardiomegaly&#xD;
&#xD;
               -  Prior myocardial infarction&#xD;
&#xD;
               -  Ventricular hypertrophy&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Poorly uncontrolled hypertension (resting diastolic blood pressure &gt; 115 mm Hg)&#xD;
&#xD;
               -  Other cardiomyopathy&#xD;
&#xD;
          -  No serious intercurrent medical or psychiatric illness&#xD;
&#xD;
          -  No serious active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 1 line of prior chemotherapy for metastatic or locally advanced disease&#xD;
             (neoadjuvant/adjuvant chemotherapy allowed)&#xD;
&#xD;
          -  No more than 10 weeks since first-line chemotherapy&#xD;
&#xD;
          -  No prior lapatinib ditosylate&#xD;
&#xD;
          -  No prior radiotherapy to the indicator lesion(s) (newly arising lesions in previously&#xD;
             irradiated areas allowed)&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent CYP3A4 inducers, including but not&#xD;
             limited to, any of the following:&#xD;
&#xD;
               -  Antibiotics (all rifamycin class agents [e.g., rifampicin, rifabutin,&#xD;
                  rifapentine])&#xD;
&#xD;
               -  Anticonvulsants (phenytoin, carbamazepine, barbiturates [e.g., phenobarbital])&#xD;
&#xD;
               -  Oral glucocorticoids (cortisone [&gt; 50 mg], hydrocortisone [&gt; 40 mg], prednisone&#xD;
                  [&gt; 10 mg], methylprednisolone [&gt; 8 mg], dexamethasone [&gt; 2 mg²])&#xD;
&#xD;
               -  St. John's wort or modafinil&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent CYP3A4 inhibitors, including but not&#xD;
             limited to, any of the following:&#xD;
&#xD;
               -  Antibiotics (clarithromycin, erythromycin, troleandomycin)&#xD;
&#xD;
               -  Antifungals (itraconazole, ketoconazole, fluconazole [&gt;150 mg daily],&#xD;
                  voriconazole)&#xD;
&#xD;
               -  Antiretrovirals/protease inhibitors (delavirdine, nelfinavir, amprenavir,&#xD;
                  ritonavir, indinavir, saquinavir, lopinavir)&#xD;
&#xD;
               -  Calcium channel blockers (verapamil, diltiazem)&#xD;
&#xD;
               -  Antidepressants (nefazodone, fluvoxamine)&#xD;
&#xD;
               -  Gastrointestinal agents (cimetidine, aprepitant)&#xD;
&#xD;
               -  Grapefruit, grapefruit juice&#xD;
&#xD;
          -  At least 6 months since prior and no concurrent amiodarone&#xD;
&#xD;
          -  No concurrent radical or curative therapy (radiotherapy or surgery) at the end of&#xD;
             first-line treatment (palliative radiotherapy allowed)&#xD;
&#xD;
          -  No other concurrent experimental or investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer treatment, including cytotoxic or specific immune&#xD;
             therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Powles, MD, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barts and the London NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Grampian - Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basildon and Thurrock University Hospital NHS Trust - Basildon Hospital</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust - Birmingham University Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth and Christchurch NHS Foundation Trust - Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Trust - Bristol University Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Trust - Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Essex NHS Trust - Broomfield Hospital</name>
      <address>
        <city>Chelmsford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester University Hospitals NHS Trust</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire NHS Trust</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derby Hospitals NHS Trust - Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - The Beatson</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calderdale and Huddersfield NHS Trust - Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital NHS Trust</name>
      <address>
        <city>Ipswich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys &amp; St Thomas' Hospital NHS Trust - Guys Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Tees NHS Trust - James Cook University Hospital</name>
      <address>
        <city>Middlesborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospitals NHS Trust</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherwood Forest Hospitals NHS Trust - Kings Mill Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barking, Havering and Redbridge NHS Trust - Queens Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taunton and Somerset NHS Trust - Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

